IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2
KRAS G12	Non Small Cell Lung Cancer	KRAS G12	Non Small Cell Lung Cancer	RMC-6236 Sensitive: C2 – Inclusion Criteria RMC-6236 Sensitive : C2	RMC-6236 Sensitive: C2 – Inclusion Criteria RMC-6236 Sensitive : C2
KRAS G12	Pancreatic Ductal Adenocarcinoma	KRAS G12	Pancreatic Ductal Adenocarcinoma	RMC-6236 Sensitive: C3 – Early Trials RMC-6236 Sensitive : C3	RMC-6236 Sensitive: C3 – Early Trials RMC-6236 Sensitive : C3
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	IODVA1 Sensitive: D – Preclinical IODVA1 Sensitive : D	IODVA1 Sensitive: D – Preclinical IODVA1 Sensitive : D
KRAS mutation	Pancreatic Ductal Adenocarcinoma	KRAS mutation	Pancreatic Ductal Adenocarcinoma	RMC-6236 Sensitive: D – Preclinical RMC-6236 Sensitive : D	RMC-6236 Sensitive: D – Preclinical RMC-6236 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	JZP815 Sensitive: D – Preclinical JZP815 Sensitive : D	JZP815 Sensitive: D – Preclinical JZP815 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	JZP815 Sensitive: D – Preclinical JZP815 Sensitive : D	JZP815 Sensitive: D – Preclinical JZP815 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib + RMC-7977 Sensitive: D – Preclinical gilteritinib + RMC-7977 Sensitive : D	gilteritinib + RMC-7977 Sensitive: D – Preclinical gilteritinib + RMC-7977 Sensitive : D
FLT3 mutation + NRAS mutation	Acute Myelogenous Leukemia	FLT3 mutation + NRAS mutation	Acute Myelogenous Leukemia	gilteritinib + RMC-7977 Sensitive: D – Preclinical gilteritinib + RMC-7977 Sensitive : D	gilteritinib + RMC-7977 Sensitive: D – Preclinical gilteritinib + RMC-7977 Sensitive : D

RAS inhibitor

RAS inhibitor

Associations(9)

Associations
(9)